What is Hydrocortisone ABM?
Hydrocortisone ABM is in a class of drugs called steroids. Hydrocortisone ABM prevents the release of substances in the body that cause inflammation.
Salicylic acid and sulfur topical (for the skin) work together to soften scales and psoriasis plaques and cause shedding of the outer layer of skin.
The combination of Hydrocortisone ABM, salicylic acid, and sulfur is used to treat inflammation, itching, flaking, scaling, and other symptoms of scalp psoriasis or seborrheic dermatitis.
This medication is supplied as a kit containing Hydrocortisone ABM lotion, salicylic acid and sulfur shampoo, and a cleansing shampoo.
Hydrocortisone ABM, salicylic acid, and sulfur may also be used for purposes not listed in this medication guide.
Hydrocortisone ABM indications
1. Endocrine Disorders
Primary or secondary adrenocortical insufficiency (hydrocortisone or Hydrocortisone ABM is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).
Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer
2. Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis
Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis
Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis
3. Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of:
Systemic lupus erythematosus
Acute rheumatic carditis
Systemic dermatomyositis (polymyositis)
4. Dermatologic Diseases
Bullous dermatitis herpetiformis
Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis
Severe seborrheic dermatitis
5. Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:
Seasonal or perennial allergic rhinitis
Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness
Drug hypersensitivity reactions
6. Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes
involving the eye and its adnexa, such as: Allergic conjunctivitis
Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis
Anterior segment inflammation
Diffuse posterior uveitis and choroiditis
7. Respiratory Diseases
Loeffler’s syndrome not manageable by other means
Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration
8. Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia
Erythroblastopenia (RBC anemia)
Congenital (erythroid) hypoplastic anemia
9. Neoplastic Diseases
For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood
10. Edematous States
To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus
11. Gastrointestinal Diseases
To tide the patient over a critical period of the disease in: Ulcerative colitis
Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy
Trichinosis with neurologic or myocardial involvement
How should I use Hydrocortisone ABM?
Use Hydrocortisone ABM as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Hydrocortisone ABM is usually given as an injection at your doctor's office, hospital, or clinic. If you will be using Hydrocortisone ABM at home, a health care provider will teach you how to use it. Be sure you understand how to use Hydrocortisone ABM. Follow the procedures you are taught when you use a dose. Contact your health care provider if you have any questions.
- Do not use Hydrocortisone ABM if it contains particles, is cloudy or discolored, or if the vial is cracked or damaged.
- Keep this product, as well as syringes and needles, out of the reach of children and pets. Do not reuse needles, syringes, or other materials. Ask your health care provider how to dispose of these materials after use. Follow all local rules for disposal.
- If you miss a dose of Hydrocortisone ABM, contact your doctor right away.
Ask your health care provider any questions you may have about how to use Hydrocortisone ABM.
Uses of Hydrocortisone ABM in details
It is used as a cream to treat mild to moderate inflammatory skin disorders such as mild to moderate eczema (itchy skin rash)contact dermatitis (e.g. after contact with certain plants, cosmetics, irritants like detergents), insect bite reactions.
Orally it is used to reduce pain, swelling and inflammation and to reduce the body's immune response. In general this drug is used to treat hormonal conditions when the body does not produce enough of its own steroids, and to treat a range of immune and allergic conditions. Hydrocortisone ABM is used as an injection for treating various conditions such as severe allergic reactions, arthritis, blood diseases, breathing problems, certain cancers, eye diseases, intestinal disorders, and skin diseases. The injectable form of Hydrocortisone ABM is used when a similar drug cannot be taken by mouth or when a very fast treatment is needed, especially in patients with severe medical conditions. This drug may also be used with other medications as a replacement for certain hormones.
Hydrocortisone ABM description
Hydrocortisone ABM contains dissolved Hydrocortisone ABM 0.5% for improved effectiveness in a special occlusive cream base. It is paraben-, lanolin- and chlorocresol-free with a pH 5.
Hydrocortisone ABM dosage
The use of Hydrocortisone ABM Rectal Suspension, USP Hydrocortisone ABM retention enema is predicated upon the concomitant use of modern supportive measures such as rational dietary control, sedatives, antidiarrheal agents, antibacterial therapy, blood replacement if necessary, etc.
The usual course of therapy is one Hydrocortisone ABM Rectal Suspension, USP nightly for 21 days, or until the patient comes into remission both clinically and proctologically. Clinical symptoms usually subside promptly within 3 to 5 days. Improvement in the appearance of the mucosa, as seen by sigmoidoscopic examination, may lag somewhat behind clinical improvement. Difficult cases may require as long as 2 or 3 months of Hydrocortisone ABM Rectal Suspension, USP treatment. Where the course of therapy extends beyond 21 days, Hydrocortisone ABM Rectal Suspension, USP should be discontinued gradually by reducing administration to every other night for 2 or 3 weeks.
If clinical or proctologic improvement fails to occur within 2 or 3 weeks after starting Hydrocortisone ABM Rectal Suspension, USP, discontinue its use.
Symptomatic improvement, evidenced by decreased diarrhea and bleeding; weight gain; improved appetite; lessened fever; and decrease in leukocytosis, may be misleading and should not be used as the sole criterion in judging efficacy. Sigmoidoscopic examination and X-ray visualization are essential for adequate monitoring of ulcerative colitis. Biopsy is useful for differential diagnosis.
Patient instructions for administering Hydrocortisone ABM Rectal Suspension, USP are enclosed in each box. It is recommended that the patient lie on their left side during administration and for 30 minutes thereafter, so that the fluid will distribute throughout the left colon. Every effort should be made to retain the enema for at least an hour and preferably, all night. This may be facilitated by prior sedation and/or antidiarrheal medication, especially early in therapy when the urge to evacuate is great.
Hydrocortisone ABM interactions
With simultaneous use of Hydrocortisone ABM increases the toxicity of cardiac glycosides (because of the emerging hypokalemia increases the risk of arrhythmias); with acetylsalicylic acid - accelerates its excretion and reduces its concentration in blood plasma (with the abolition of Hydrocortisone ABM concentration of salicylates in the blood increases, and increases the risk of side effects); with paracetamol - increased risk of hepatotoxic action of paracetamol (induction of hepatic enzymes and formation of a toxic metabolite of paracetamol); with cyclosporine - increased side effects of Hydrocortisone ABM as a result of inhibition of its metabolism; with ketoconazole - increased side effects of Hydrocortisone ABM as a result of reduction of its clearance.
Hydrocortisone ABM ICM Pharma reduces the effectiveness of hypoglycemic; intensifies the effect of indirect anticoagulants of coumarin derivatives.
Hydrocortisone ABM reduces the effect of vitamin D on the absorption of calcium ions into the lumen of the intestine. Ergocalciferol and parathyroid hormone hinder the development of osteopathy caused by GCS.
Hydrocortisone ABM ICM Pharma increases the metabolism of isoniazid, meksiletina (especially in "fast acetylators"), which leads to a decrease in their plasma concentrations; increases (with prolonged therapy) the content of folic acid reduces the concentration of praziquantel in blood.
Hydrocortisone ABM in high doses reduces the effect somatropina.
Hypokalemia caused by GCS, may increase the severity and duration of muscle blockade on the background of muscle relaxants.
Antacids reduce the absorption of the GCS.
At simultaneous application with SCS thiazides, carbonic anhydrase inhibitors, other GCS, amphotericin B increase the risk of hypokalemia, drugs containing sodium ions - swelling and increase blood pressure.
NSAIDs and ethanol increases the risk of gastrointestinal ulcerations and bleeding, in combination with NSAIDs to treat arthritis may reduce the dose of GCS due to summation of therapeutic effect. Indomethacin displacing the SCS from its association with albumin, increases the risk of its side effects.
Amphotericin B and carbonic anhydrase inhibitors increase the risk of osteoporosis.
The therapeutic effect of GCS is reduced under the influence of inducers of microsomal liver enzymes (including phenytoin, barbiturates, ephedrine, theophylline, rifampin) due to increased rate of metabolism of these substances.
Inhibitors of the function of the adrenal cortex (including mitotan) may necessitate higher doses of GCS.
Clearance GCS increased against the background of preparations of thyroid hormones.
Immunosuppressants increase the risk of infection and lymphoma or other lymphoproliferative disorders associated with Epstein-Barr virus.
Estrogens (including oral contraceptives containing estrogen) reduce the clearance of GKS, lengthens T1/2 and their therapeutic and toxic effects. The appearance of hirsutism and acne promotes the simultaneous use of other steroid hormone funds - androgens, estrogens, anabolic steroids, oral contraceptives.
Tricyclic antidepressants may increase the severity of depression caused by GCS (not shown for the treatment of these side effects).
The risk of developing cataracts increases with the application against other GCS antipsychotic funds (neuroleptics), carbutamide and azathioprine. Simultaneous of Hydrocortisone ABM ICM Pharma with the appointment of m-cholinoblockers, as well as with means having m-anticholinergic action (including antihistamines, tricyclic antidepressants), with nitrates improves the intraocular pressure.
With simultaneous application of SCS with live vaccines and antiviral compared to other types of immunization increases the risk of activation of viruses and development of infections.
Hydrocortisone ABM side effects
Applies to Hydrocortisone ABM: oral suspension, oral tablet
In addition to its needed effects, some unwanted effects may be caused by Hydrocortisone ABM. In the event that any of these side effects do occur, they may require medical attention.
Major Side Effects
You should check with your doctor immediately if any of these side effects occur when taking Hydrocortisone ABM:
- blurred vision
- decrease in the amount of urine
- fast, slow, pounding, or irregular heartbeat or pulse
- mental depression
- mood changes
- noisy, rattling breathing
- numbness or tingling in the arms or legs
- pounding in the ears
- shortness of breath
- swelling of the fingers, hands, feet, or lower legs
- trouble thinking, speaking, or walking
- troubled breathing at rest
- weight gain
- Abdominal cramping and/or burning (severe)
- abdominal pain
- bloody, black, or tarry stools
- cough or hoarseness
- darkening of skin
- decrease in height
- decreased vision
- dry mouth
- eye pain
- eye tearing
- facial hair growth in females
- fever or chills
- flushed, dry skin
- fruit-like breath odor
- full or round face, neck, or trunk
- heartburn and/or indigestion (severe and continuous)
- increased hunger
- increased thirst
- increased urination
- loss of appetite
- loss of sexual desire or ability
- lower back or side pain
- menstrual irregularities
- muscle pain or tenderness
- muscle wasting or weakness
- pain in back, ribs, arms, or legs
- painful or difficult urination
- skin rash
- trouble healing
- trouble sleeping
- unexplained weight loss
- unusual tiredness or weakness
- vision changes
- vomiting of material that looks like coffee grounds
Minor Side Effects
Some of the side effects that can occur with Hydrocortisone ABM may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:
- Increased appetite
- Abnormal fat deposits on the face, neck, and trunk
- dry scalp
- lightening of normal skin color
- red face
- reddish purple lines on the arms, face, legs, trunk, or groin
- swelling of the stomach area
- thinning of the scalp hair
Hydrocortisone ABM contraindications
For short-term use of Hydrocortisone ABM Sunward Pharmaceutical according to the life - hypersensitivity to Hydrocortisone ABM. For intraarticular administration and injection directly into the lesion: previous arthroplasty, abnormal bleeding (endogenous or caused by the use of anticoagulants), intra-articular fracture, infection (septic) inflammatory process in joints and periarticular infections (including history), and also general infectious disease marked juxta-articular osteoporosis, lack of signs of inflammation in the joint ("dry" joint, such as osteoarthrosis without synovitis), marked bone destruction and deformity of joints (sharp narrowing of joint space, ankylosis), instability of the joint as a result of arthritis, aseptic necrosis of the epiphyses of bones forming the joint.
For external use: bacterial, viral, fungal skin diseases, tuberculosis, skin, cutaneous manifestations of syphilis, tumors of the skin, post-vaccination period, violation of the integrity of the skin (ulcers, wounds), children's age (up to 2 years, with itching in the anal area - up to 12 years), rosacea, acne vulgaris, perioral dermatitis.
For use in ophthalmology: bacterial, viral, fungal eye diseases, tuberculosis eye disease, trachoma, violation of the integrity of the eye epithelium.
Hydrocortisone ABM pregnancy
Hydrocortisone ABM has not been assigned to an FDA pregnancy category. Animal studies involving corticosteroids have revealed evidence of an increased incidence of cleft palate in offspring. There are no controlled data in human pregnancy, however, corticosteroids have been used during human pregnancy without evidence of teratogenicity. Hydrocortisone ABM should be given during pregnancy only when benefit outweighs risk.
Hydrocortisone ABM overdose
Reports of acute toxicity and/or death following overdosage of glucocorticoids are rare. In the event of overdosage, no specific antidote is available, treatment is supportive and symptomatic.
The intraperitoneal LD50 of Hydrocortisone ABM in female mice was 1740 mg/kg.
Hydrocortisone ABM precautions
Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. Manifestations of Cushing’s syndrome, hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment.
Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests.
Hydrocortisone ABM Ointment has produced mild, reversible adrenal suppression in adult patients when used under occlusion for 5 days, 15 grams twice a day over 25 to 60% body surface area or when used three times a day over 20 to 30% body surface area to treat psoriasis for 3-4 weeks.
If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur, requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for these products.
Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios.
If irritation develops, Hydrocortisone ABM (hydrocortisone valerate ointment) Ointment, 0.2% should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation, as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing.
If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of Hydrocortisone ABM Ointment should be discontinued until the infection has been adequately controlled.
Information for Patients
Patients using topical corticosteroids should receive the following information and instructions:
- This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
- This medication should not be used for any disorder other than that for which it was prescribed.
- The treated skin area should not be bandaged, otherwise covered or wrapped, so as to be occlusive unless directed by the physician.
- Patients should report to their physician any signs of local adverse reactions.
- Hydrocortisone ABM Ointment should not be applied in the diaper areas as diapers or plastic pants may constitute occlusive dressings.
- This medication should not be used on the face, underarms, or groin areas unless directed by the physician.
- As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, contact the physician.
The following tests may be helpful in evaluating patients for HPA axis suppression:
ACTH stimulation test
A.M. plasma cortisol test
Urinary free cortisol test
Carcinogenesis, Mutagenesis, and Impairment of Fertility
Long-term animal studies have not been performed to evaluate the carcinogenic potential of Hydrocortisone ABM valerate.
Hydrocortisone ABM Ointment was shown to be non-mutagenic in the Ames-Salmonella/Microsome Plate Test.
There are no studies which assess the effects of Hydrocortisone ABM valerate on fertility and general reproductive performance.
Teratogenic Effects, Pregnancy Category C
Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.
Dermal embryofetal developmental studies were conducted in rabbits and rats with Hydrocortisone ABM valerate cream, 0.2%. Hydrocortisone ABM valerate cream, 0.2%, was administered topically for 4 hours/day, rather than the preferred 24 hours/day, during the period of organogenesis in rats (gestational days 5-16) and rabbits (gestational days 6-19).
Topical doses of Hydrocortisone ABM valerate up to 9 mg/kg/day (54 mg/m2/day) were administered to rats and 5 mg/kg/day (60 mg/m2/day) were administered to rabbits. In the absence of maternal toxicity, a significant increase in delayed skeletal ossification in fetuses was noted at 9 mg/kg/day [2.5X the Maximum Recommended Human Dose (MRHD) based on body surface area (BSA) comparisons] in the rat study. No malformations in the fetuses were noted at 9 mg/kg/day (2.5X MRHD based on BSA comparisons) in the rat study. Indicators of embryofetal toxicity, significant decrease in fetal weight at 2 mg/kg/day (1X MRHD based on BSA) and a significant increase in post-implantation loss and embryo resorption at 5 mg/kg (3X MRHD based on BSA), were noted in the rabbit study. A significant increase in delayed skeletal ossification in fetuses was noted at 5 mg/kg/day (3X the MRHD based on BSA comparisons) in the rabbit study. Increased numbers of fetal malformations (e.g., cleft palate, omphalocele and clubbed feet) were noted at 5 mg/kg/day (3X MRHD based on BSA comparisons) in the rabbit study.
There are no adequate and well-controlled studies in pregnant women. Hydrocortisone ABM (hydrocortisone valerate ointment) Ointment, 0.2% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when Hydrocortisone ABM Ointment is administered to a nursing woman.
Safety of this product in pediatric patients has not been established. There is no data on adrenal suppression and/or growth suppression.
Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression and Cushing’s syndrome when they are treated with topical corticosteroids. They are therefore also at a greater risk of adrenal insufficiency during and/or after withdrawal of treatment. Adverse effects including striae have been reported with inappropriate use of topical corticosteroids in infants and children.
HPA axis suppression, Cushing’s syndrome, linear growth retardation, delayed weight gain, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels, and an absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
Clinical studies ofWestcort Ointment, 0.2% did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
Active ingredient matches for Hydrocortisone ABM:
Hydrocortisone in New Zealand.
List of Hydrocortisone ABM substitutes (brand and generic names)
|Sort by popularity|
|Unit description / dosage (Manufacturer)||Price, USD|
|Cream; Topical; Hydrocortisone 0.5%|
|Hydrocortisoni PCH (Netherlands)|
|Hydrocortisonum (Lithuania, Poland)|
|Hydrocortisonum 10 Bottle|
|Hydrocortisonum 1% Aflofarm (Poland)|
|Hydrocortisonum Aflofarm (Poland)|
|Hydrocortisonum AFP (Poland)|
|Hydrocortisonum Homeofarm (Poland)|
|Hydrocortisonum Jelfa (Latvia, Poland)|
|Hydrocortisonum Oceanic (Poland)|
|Hydrocortisonum Polfa (Lithuania)|
|Hydrocortistab (United Kingdom)|
|Injectable; Injection; Hydrocortisone Acetate 2.5% (Sovereign)|
|Hydrocortisyl (Ethiopia, Ireland, Malta)|
|Hydrocortone (Austria, Ireland, Japan, Portugal, Switzerland, United States)|
|Injectable; Injection; Hydrocortisone Sodium Phosphate 25 mg / ml (Auden mckenzie)|
|Injectable; Injection; Hydrocortisone Sodium Phosphate 50 mg / ml (Auden mckenzie)|
|Ointment; Ophthalmic, Otic; Hydrocortisone Sodium Phosphate 1.5% (Auden mckenzie)|
|Tablet; Oral; Hydrocortisone Sodium Phosphate 10 mg (Auden mckenzie)|
|Tablet; Oral; Hydrocortisone Sodium Phosphate 20 mg (Auden mckenzie)|
|Tablets; Oral; Hydrocortisone Sodium Phosphate 10 mg (Auden mckenzie)|
|Tablets; Oral; Hydrocortisone Sodium Phosphate 20 mg (Auden mckenzie)|
|Ointment; Topical; Hydrocortisone Acetate 1% (Dermapharm)|
|Hydrocutan 0.25% (Germany)|
|Hydrocutan 1% (Germany)|
|Hydrocutan Creme (Germany)|
|Hydrocutan Mild (Germany)|
|Ointment; Topical; Hydrocortisone 1% (Dermapharm)|
|Hydrocutan Salbe (Germany)|
|Hydrocutan Tabletten (Germany)|
|Hydroderm Aesca (Austria)|
|Hydroderm HC (Germany)|
|Cream; Topical; Hydrocortisone 0.5% (Karrer)|
|Cream; Topical; Hydrocortisone (Galen)|
|Lotion; Topical; Hydrocortisone (Galen)|
|Ointment; Topical; Hydrocortisone (Galen)|
|Solution; Topical; Hydrocortisone (Galen)|
|Hydrokortison CCS (Norway, Sweden)|
|Hydrokortison Clean Chemical Sweden (Sweden)|
|Hydrokortison DnE (Denmark)|
|Hydrokortison Galderma (Denmark, Norway)|
|Hydrokortison Nycomed (Denmark, Sweden)|
- DailyMed. "CIPROFLOXACIN HYDROCHLORIDE; HYDROCORTISONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "hydrocortisone". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "hydrocortisone". http://www.drugbank.ca/drugs/DB00741 (accessed September 17, 2018).
- DTP/NCI. "hydrocortisone: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).
- Wikipedia. "cortisol: Link to the compound information in Wikipedia.". https://en.wikipedia.org/wiki/Cortis... (accessed September 17, 2018).
ReviewsThe results of a survey conducted on ndrugs.com for Hydrocortisone ABM are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Hydrocortisone ABM. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology